Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Raynaud Phenomenon
Interventions
DRUG

Udenafil or Amlodipine

Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Dong-A Pharmaceutical Co., Ltd.

INDUSTRY

lead

Seoul National University Hospital

OTHER